Premium
Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats
Author(s) -
Jung Klaus,
Krell HansWilli,
Ortel Bernhard,
Hasan Tayyaba,
Römer Andreas,
Schnorr Dietmar,
Loening Stefan A.,
Lein Michael
Publication year - 2002
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.10183
Subject(s) - prostate cancer , matrix metalloproteinase , prostate , medicine , cancer , zymography , tumor progression , pathology , tissue inhibitor of metalloproteinase , endocrinology
Background Matrix metalloproteinases (MMPs) play an important role in invasion and metastatic spread of cancer cells. The objective of this study was to assess MMPs in plasma of Dunning tumor rats as indicators of the progression of prostate cancer and follow‐up parameters after treatment. Methods Prostate cancer was induced in male Copenhagen rats by either subcutaneous or orthotopic implantation of R3327‐MatLyLu cells. During the development of the tumor, plasma MMP‐2, and MMP‐9 were measured by gelatin‐substrate zymography and Western blot technique with densitometry in untreated animals, rats treated with laser‐induced hyperthermia, or with the new synthetic MMP inhibitor RO 28‐2653. Results Normal prostatic tissue of the Copenhagen rats predominantly expressed proMMP‐2 but not proMMP‐9 whereas MMP‐9 was only found in cancerous tissue. Elevated plasma MMP‐9 values were demonstrated in rats with subcutaneous or orthotopic tumors. Animals with tumors and treated with the MMP inhibitor RO 28‐2653 had both a lower tumor volume and a lower plasma MMP‐9 concentration compared with controls. Conclusions The determination of plasma MMP‐9 in Dunning tumor rats is a useful tool to monitor the progression of prostate cancer and to assess the efficacy of drugs like MMP inhibitors or other treatment protocols. Prostate 54: 206–211, 2003. © 2002 Wiley‐Liss, Inc.